Zobrazeno 1 - 10
of 45
pro vyhledávání: '"C. Murias"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
J Burgos-Burgos, D Macias-Verde, Pedro C. Lara, E Vicente, V Vega, V Gómez, J Travieso, M Travieso-Aja, J Ospina, C Santana, C Murias
Publikováno v:
Clinical and Translational Oncology. 23:2579-2583
Hypofractionated whole breast irradiation (hWBI) and intraoperative radiotherapy (IORT) could be associated in breast cancer patients showing high-risk factors of local recurrence after breast conserving therapy (BSC). The aim of this trial was to ev
Autor:
Maia Gogiladze, Amy McCullough, Andrew M Wardley, Chao Li, Boris Krastev, Andrew P. Beelen, Marina Maglakelidze, Rajesh K. Malik, Iurie Bulat, Yili Pritchett, Richard D. Baird, C. Murias, Jessica A. Sorrentino, Adrian Crijanovschi, R Roylance
Publikováno v:
Cancer Research. 80:P1-19
Approved CDK4/6 inhibitors have demonstrated significant improvements in progression free survival when combined with fulvestrant in patients with HR+/HER2- advanced breast cancer, though limited by neutropenia and gastrointestinal side effects. Lero
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hendrik-Tobias Arkenau, Sabeeh Butt, Maria Reyes Gonzalez-Exposito, Muhammad S Khan, Anna Patrikidou, C. Murias
Publikováno v:
Annals of Urologic Oncology (2019)
As research focus in oncology has recently shifted to immunomodulation, the era of introduction of immunotherapeutic agents in the management of prostate cancer has just begun. With the success of checkpoint blockade drugs in certain advanced tumours
Autor:
Erika Hamilton, C. Murias, Daniel C. Cho, Patricia LoRusso, Kevin Kalinsky, Patrick A. Ott, Matthias Will, V Huels, B Benson, Sylvia Adams, H.-T. Arkenau
Publikováno v:
Cancer Research. 79:P6-18
Background: Probody™ therapeutics are novel, fully recombinant antibody prodrugs designed to remain relatively inactive in healthy tissue and to be specifically activated by proteases in the tumor microenvironment. In this way, Probody therapeutics
Autor:
Vincenzo Formica, Mario Roselli, A. Nardecchia, Cristina Morelli, C. Murias, Kai-Keen Shiu, Sabeeh Butt, Hendrik-Tobias Arkenau, Anna Patrikidou, Nicola Renzi, Jessica Lucchetti
Publikováno v:
Targeted oncology. 15(3)
Immune checkpoint inhibitors (ICIs) demonstrated improved overall survival (OS) in heavily pretreated unselected patients with metastatic gastro-esophageal junction (mGOJ)/gastric cancer (GC). Attempts to select patients based on programmed death-lig
Autor:
John Pollard, Penney, Sara M. Tolaney, H.-T. Arkenau, Geoffrey I. Shapiro, C. Murias, Simon Lord, Emma Dean, G. Conboy, Rui Tang, Carlos Becerra, Melinda L. Telli, Vandana G. Abramson, S.Z. Fields
Publikováno v:
Cancer Research. 78:OT2-07
Background: ATR is a critical regulator of the cellular response to replication stress; it signals DNA damage repair, mediated through homologous recombination. Many cancers depend on ATR to survive DNA damage. M6620 is a potent, selective inhibitor
Autor:
R Roylance, B. Krastev, Wenli Tao, Richard D. Baird, M. Maglakelidze, H-T. Arkenau, A. Crijanovschi, Jessica A. Sorrentino, C. Murias, I. Bulat, Ruhi Rai, Andrew P. Beelen, Andrew M Wardley, M. Gogiladze
Publikováno v:
Annals of Oncology. 31:S351-S352